Advances in Hematology / 2020 / Article / Tab 2

Clinical Study

Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients

Table 2

The comparison between the one-stage assay versus chromogenic assay for the measurement of factor VIII levels in the individual cases.

Patient IDAgeNOne-stage assay†Chromogenic assay†Mean differenceSE value95% CI

Patient 12550.04 (0.06)0.23 (0.15)−0.190.040.009−0.31 to −0.08
Patient 22440.03 (0.05)0.15 (0.03)−0.120.040.063−0.25 to 0.012
Patient 35740.34 (0.37)0.46 (0.48)−0.110.050.123−0.29 to 0.05
Patient 43250.01 (0.01)0.12 (0.07)−0.110.030.03−0.20 to −0.17
Patient 52850.05 (0.05)0.04 (0.05)0.0040.0020.178−0.002 to 0.01
Patient 62440.05 (0.06)0.05 (0.07)−0.0020.0020.391−0.010 to 0.005
Patient 71010.040.09−0.05NANANA
Patient 83050.06 (0.08)0.14 (0.13)−0.0760.0250.040−0.14 to −0.005
Patient 92620.01 (0.11)0.14 (0.14)−0.0450.0250.323−0.36 to 0.27
Patient 103450.06 (0.08)0.07 (0.09)−0.0080.0070.033−0.02 to −0.12
Patient 113670.03 (0.04)0.04 (0.04)−0.0050.0020.103−0.01 to −0.001
Patient 122950.12 (0.14)0.17 (0.19)−0.0520.0240.104−0.12 to 0.016
Patient 131030.17 (0.11)0.25 (0.14)−0.0830.0200.054−0.17 to 0.003
Patient 141010.010.010NANANA

N = number of samples evaluated; † data reported in mean (standard deviation); SE = standard error; CI = confidence interval; NA = not applicable since one sample was available.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.